↓ Skip to main content

Cytokine Inhibition in Patients With Chronic Fatigue Syndrome

Overview of attention for article published in Annals of Internal Medicine, March 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news
13 news outlets
blogs
1 blog
twitter
59 tweeters
peer_reviews
1 peer review site
facebook
8 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cytokine Inhibition in Patients With Chronic Fatigue Syndrome
Published in
Annals of Internal Medicine, March 2017
DOI 10.7326/m16-2391
Pubmed ID
Authors

Megan E. Roerink, Sebastian J.H. Bredie, Michael Heijnen, Charles A. Dinarello, Hans Knoop, Jos W.M. Van der Meer

Abstract

Interleukin-1 (IL-1), an important proinflammatory cytokine, is suspected to play a role in chronic fatigue syndrome (CFS). To evaluate the effect of subcutaneous anakinra versus placebo on fatigue severity in female patients with CFS. Randomized, placebo-controlled trial from July 2014 to May 2016. Patients, providers, and researchers were blinded to treatment assignment. (ClinicalTrials.gov: NCT02108210). University hospital in the Netherlands. 50 women aged 18 to 59 years with CFS and severe fatigue leading to functional impairment. Participants were randomly assigned to daily subcutaneous anakinra, 100 mg (n = 25), or placebo (n = 25) for 4 weeks and were followed for an additional 20 weeks after treatment (n = 50). The primary outcome was fatigue severity, measured by the Checklist Individual Strength subscale (CIS-fatigue) at 4 weeks. Secondary outcomes were level of impairment, physical and social functioning, psychological distress, and pain severity at 4 and 24 weeks. At 4 weeks, 8% (2 of 25) of anakinra recipients and 20% (5 of 25) of placebo recipients reached a fatigue level within the range reported by healthy persons. There were no clinically important or statistically significant differences between groups in CIS-fatigue score at 4 weeks (mean difference, 1.5 points [95% CI, -4.1 to 7.2 points]) or the end of follow-up. No statistically significant between-group differences were seen for any secondary outcome at 4 weeks or the end of follow-up. One patient in the anakinra group discontinued treatment because of an adverse event. Patients in the anakinra group had more injection site reactions (68% [17 of 25] vs. 4% [1 of 25]). Small sample size and wide variability in symptom duration; inclusion was not limited to patients with postinfectious symptoms. Peripheral IL-1 inhibition using anakinra for 4 weeks does not result in a clinically significant reduction in fatigue severity in women with CFS and severe fatigue. Interleukin Foundation and an independent donor who wishes to remain anonymous.

Twitter Demographics

The data shown below were collected from the profiles of 59 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 45 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 17%
Researcher 5 11%
Student > Postgraduate 5 11%
Professor 4 9%
Student > Bachelor 4 9%
Other 13 28%
Unknown 7 15%
Readers by discipline Count As %
Medicine and Dentistry 20 43%
Biochemistry, Genetics and Molecular Biology 4 9%
Nursing and Health Professions 3 7%
Neuroscience 3 7%
Psychology 3 7%
Other 6 13%
Unknown 7 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 137. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2017.
All research outputs
#135,802
of 15,239,574 outputs
Outputs from Annals of Internal Medicine
#678
of 11,347 outputs
Outputs of similar age
#5,168
of 260,475 outputs
Outputs of similar age from Annals of Internal Medicine
#37
of 158 outputs
Altmetric has tracked 15,239,574 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,347 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 41.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,475 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 158 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.